Background-During medical checkups of two unrelated female outpatients during their annual health examination and one male inpatient suVering from cardiac failure the glycated haemoglobin (HbA 1C ) concentrations measured by high performance liquid chromatography (HPLC) were low, in spite of normal fasting plasma glucose concentrations. However, HbA 1C concentrations measured by latex immunoagglutination and fructosamine concentrations were within the normal range. Method-Investigations were performed to elucidate the reasons for these discrepancies.
Glycated haemoglobin (HbA 1C ) has been shown to be increased in diabetes mellitus 1 and is widely used as a marker for long term glycaemic status. Analysis of HbA 1C is performed by high performance liquid chromatography (HPLC), electrophoresis, immunoassay, and colorimetry, as well as other methods. Among them, HPLC is generally used as the standard method for the determination of HbA 1C concentrations. 2 3 However, the HbA 1C concentration is aVected by several factors other than blood glucose concentrations, such as uraemia, 4 alcohol abuse, 5 high dose aspirin intake, 6 hyperbilirubinaemia, 7 and the decreased life span of erythrocytes 8 Direct sequencing of haemoglobin cDNA in KM and TY was performed according to the following method. Total RNA was obtained from peripheral blood cells by guanidium thiocyanate/phenol/chloroform extraction 10 and then cDNA was reverse transcribed from the total RNA. Table 1 shows the primers for the polymerase chain reaction (PCR), which were used under the following conditions: cDNA was denatured at 94°C for five minutes, followed by 30 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for one minute, with a final extension step of seven minutes. PCR was carried out in a volume of 25 µl containing 50 mM KCl, 10 mM Tris/HCl (pH 8.8), 1.5 mM MgCl 2 , 0.1% Triton X-100, 200 µM each of dATP, dCTP, dGTP, and dTTP, 0.1 µg of cDNA, 10 pmol of each primer, and 1.5 U of Taq polymerase in a DNA thermal cycler (Perkin Elmer, Foster City, California, USA). Amplified DNA products were sequenced by the dye termination method using a DNA sequencing kit (Perkin Elmer) with the same primers as for the PCR, and analysed by means of an ABI PRISM 310 (Applied Biosystems, Foster City, California, USA). Amino acid structural analysis of abnormal haemoglobin in ES was performed as follows. Isolation of the abnormal haemoglobin -chain was carried out by means of CM-52 cellulose column chromatography, and peptide obtained by tryptic digestion of the aminoethylated abnormal haemoglobin was analysed by reversed phase HPLC (TSK gel 80Ts, 4.6 × 250 mm, Tosoh; elution buVer, 0.1% TFA/50% acetonitril-0.1% TFA/50 min; flow rate, 0.7 ml/min; detection wavelength, 214 nm). The amino acid composition of the hydrolysates of the abnormal peptide was analysed using an automatic amino acid analyser.
Results
Laboratory data revealed normal fasting blood sugar (850 mg/litre in KM, 950 mg/litre in TY, and 990 mg/litre in ES), although the concentrations of glycated haemoglobin were low: 1.2% in KM, 0.9% in TY, and 2.7% in ES.
HbA 1C concentrations measured by latex immunoagglutination were normal, as were routine haematological data. Indices suggesting haemolysis, such as indirect bilirubin or lactate dehydrogenase, were normal. HPLC chromatograms showed an additional peak near HbA 1a+b ( fig 1, Hb Takamatsu; fig 2, Hb G-Szuhu). Isoelectric focusing gel electrophoresis demonstrated an additional haemoglobin migrating faster than HbA 1 in KM and TY (fig 3) , and an additional haemoglobin migrating slower than HbA 1 in ES (fig 4) . Abnormal haemoglobin accounted for 43% (KM), 45% (TY), and 44% (ES) of the total haemoglobin. cDNA sequence and amino acid analyses of the -chain and -chain of the patients' haemoglobin disclosed that lysine at position 120 of the -chain was replaced by glutamine in KM and TY (fig 5) , and asparagine at position 80 of the -chain was replaced 
Discussion
We report two unrelated non-diabetic patients and one patient with cardiac failure with the silent haemoglobin variants Hb Takamatsu and Hb G-Szuhu. They were found incidentally during a medical checkup that included HbA 1C determination.
HbA 1C has been used as a routine clinical laboratory marker for evaluating long term glycaemic control. However, several factors are known to aVect its concentration. They include uraemia, 4 alcohol abuse, 5 high dose aspirin intake, 6 and massive bleeding, as well as various kinds of haemoglobinopathies. Uraemia, alcohol abuse, and high dose aspirin intake cause falsely high HbA 1C concentrations, whereas bleeding, haemolytic anaemia, and pregnancy cause falsely low concentrations. However, in the present cases, the factors that typically cause low HbA 1C concentrations were excluded, and it was shown that the disparity between low HbA 1C concentration and normal fasting blood sugar could be ascribed to abnormal concentrations of haemoglobins Hb Takamatsu and Hb G-Szuhu. Among the methods available for HbA 1C determination, HPLC with a cation exchange column is widely used as the standard method. The haemoglobins (Hb Takamatsu and Hb G-Szuhu) from our patients caused falsely low HbA 1C concentrations as estimated by HPLC. In HPLC, the peak of Hb Takamatsu and Hb G-Szuhu is included in the Hb 1a+b peak calculation, leading to falsely low HbA 1C results. In Hb Takamatsu, lysine at position 120 of the -chain is substituted for glutamine, while in Hb G-Szuhu, asparagine at position of 80 of the -chain is substituted for lysine. However, these haemoglobinopathies disturb neither the oxygenation/deoxygenation function, nor the stability of the haemoglobin molecule 11 because these mutations do not aVect heme contacts or 1 1 contacts. In fact, one carrier of Hb Takamatsu complained of dyspnea on exertion because of mitral valvular disease, but the other was asymptomatic and showed no haematological abnormalities. The male patient with Hb G-Szuhu in our study suVered from cardiac failure as a result of aortic and mitral regurgitation. However, these valve dysfunctions were not considered to be symptoms of this haemoglobinopathy, although the patient described by Imai et al showed mild polycythaemia. 13 Therefore, both Hb Takamatsu and Hb G-Szuhu are considered to be asymptomatic haemoglobin variants.
Hb Takamatsu was first reported by Iuchi et al in 1980.
11 The subject was a 38 year old woman who underwent a surgical operation for uterine cancer in 1979, and by 1987 16 families with Hb Takamatsu had been described in Japan. Hb G-Szuhu was first reported by Blackwell et al in 1969, 12 and 24 cases of Hb G-Szuhu had been found in Japan by 1996 (T Harano, 1996, personal communication). Over 700 abnormal haemoglobins have been described throughout the world.
14 One fifth of the haemoglobinopathies show symptoms such as cyanosis, 15 16 polycythaemia, 17 haemolysis and/or anaemia, [18] [19] [20] whereas the remaining four fifths are asymptomatic. Most of the cases are accompanied by changes in electric charge because of the substitution of amino acids, resulting in an abnormal HPLC elution pattern. Hb Takamatsu and Hb G-Szuhu are not the only haemoglobinopathies that result in falsely low HbA 1C concentrations. Others include HbC and HbS, as well as HbO Val-Leu-Gly-Ala-Phe-Ser-Asp-Gly-Leu-Ala-His-Leu-Asp-Asn-Leu-Lys ↓ Abnormal Tp-9:
Lys
